121 related articles for article (PubMed ID: 30018737)
1. An evaluation
Tesson M; Vasan R; Hock A; Nixon C; Rae C; Gaze M; Mairs R
Oncotarget; 2018 Jun; 9(49):29082-29096. PubMed ID: 30018737
[TBL] [Abstract][Full Text] [Related]
2. p53-Mediated Radiosensitization of
Lundsten S; Berglund H; Jha P; Krona C; Hariri M; Nelander S; Lane DP; Nestor M
Biomolecules; 2021 Nov; 11(11):. PubMed ID: 34827693
[TBL] [Abstract][Full Text] [Related]
3. p53 stabilisation potentiates [
Berglund H; Salomonsson SL; Mohajershojai T; Gago FJF; Lane DP; Nestor M
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):768-778. PubMed ID: 37823909
[TBL] [Abstract][Full Text] [Related]
4. Preliminary evaluation of prostate-targeted radiotherapy using (131) I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs.
Tesson M; Rae C; Nixon C; Babich JW; Mairs RJ
J Pharm Pharmacol; 2016 Jul; 68(7):912-21. PubMed ID: 27139157
[TBL] [Abstract][Full Text] [Related]
5. Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma.
de Lange J; Ly LV; Lodder K; Verlaan-de Vries M; Teunisse AF; Jager MJ; Jochemsen AG
Oncogene; 2012 Mar; 31(9):1105-16. PubMed ID: 21765463
[TBL] [Abstract][Full Text] [Related]
6. Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with
Delbart W; Marin G; Stamatopoulos B; de Wind R; Sirtaine N; Demetter P; Vercruyssen M; Woff E; Karfis I; Ghanem GE; Flamen P; Wimana Z
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190261
[TBL] [Abstract][Full Text] [Related]
7. [131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter.
McCluskey AG; Boyd M; Ross SC; Cosimo E; Clark AM; Angerson WJ; Gaze MN; Mairs RJ
Clin Cancer Res; 2005 Nov; 11(21):7929-37. PubMed ID: 16278418
[TBL] [Abstract][Full Text] [Related]
8. Multimodal Somatostatin Receptor Theranostics Using [(64)Cu]Cu-/[(177)Lu]Lu-DOTA-(Tyr(3))octreotate and AN-238 in a Mouse Pheochromocytoma Model.
Ullrich M; Bergmann R; Peitzsch M; Zenker EF; Cartellieri M; Bachmann M; Ehrhart-Bornstein M; Block NL; Schally AV; Eisenhofer G; Bornstein SR; Pietzsch J; Ziegler CG
Theranostics; 2016; 6(5):650-65. PubMed ID: 27022413
[TBL] [Abstract][Full Text] [Related]
9. Optimizing the Schedule of PARP Inhibitors in Combination with
Hallqvist A; Svensson J; Hagmarker L; Marin I; Rydén T; Beauregard JM; Bernhardt P
Biomedicines; 2021 Oct; 9(11):. PubMed ID: 34829796
[No Abstract] [Full Text] [Related]
10. Enhancing the therapeutic effects of in vitro targeted radionuclide therapy of 3D multicellular tumor spheroids using the novel stapled MDM2/X-p53 antagonist PM2.
Mortensen ACL; Morin E; Brown CJ; Lane DP; Nestor M
EJNMMI Res; 2020 Apr; 10(1):38. PubMed ID: 32300907
[TBL] [Abstract][Full Text] [Related]
11. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
Kaltsas GA; Papadogias D; Makras P; Grossman AB
Endocr Relat Cancer; 2005 Dec; 12(4):683-99. PubMed ID: 16322317
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
13. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
14. A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of
Sundquist F; Georgantzi K; Jarvis KB; Brok J; Koskenvuo M; Rascon J; van Noesel M; Grybäck P; Nilsson J; Braat A; Sundin M; Wessman S; Herold N; Hjorth L; Kogner P; Granberg D; Gaze M; Stenman J
Front Pediatr; 2022; 10():836230. PubMed ID: 35359899
[TBL] [Abstract][Full Text] [Related]
15. Improved therapy for neuroblastoma using a combination approach: superior efficacy with vismodegib and topotecan.
Chaturvedi NK; McGuire TR; Coulter DW; Shukla A; McIntyre EM; Sharp JG; Joshi SS
Oncotarget; 2016 Mar; 7(12):15215-29. PubMed ID: 26934655
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of cobalt-labeled octreotide analogs for molecular imaging and auger electron-based radionuclide therapy.
Thisgaard H; Olsen BB; Dam JH; Bollen P; Mollenhauer J; Høilund-Carlsen PF
J Nucl Med; 2014 Aug; 55(8):1311-6. PubMed ID: 24876207
[TBL] [Abstract][Full Text] [Related]
17. Experimental treatment of neuroblastoma using [131I]meta-iodobenzylguanidine and topotecan in combination.
McCluskey AG; Boyd M; Pimlott SL; Babich JW; Gaze MN; Mairs RJ
Br J Radiol; 2008 Oct; 81 Spec No 1():S28-35. PubMed ID: 18819996
[TBL] [Abstract][Full Text] [Related]
18. Radiation exposure to comforters and carers during paediatric molecular radiotherapy.
Gains JE; Walker C; Sullivan TM; Waddington WA; Fersht NL; Sullivan KP; Armstrong E; D'Souza DP; Aldridge MD; Bomanji JB; Gaze MN
Pediatr Blood Cancer; 2015 Feb; 62(2):235-239. PubMed ID: 25284346
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic effect of m-[131I]- and m-[125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes.
Weber W; Weber J; Senekowitsch-Schmidtke R
Cancer Res; 1996 Dec; 56(23):5428-34. PubMed ID: 8968097
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.
Daniel RA; Rozanska AL; Thomas HD; Mulligan EA; Drew Y; Castelbuono DJ; Hostomsky Z; Plummer ER; Boddy AV; Tweddle DA; Curtin NJ; Clifford SC
Clin Cancer Res; 2009 Feb; 15(4):1241-9. PubMed ID: 19174487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
